Join Free For Buyer|Sign In

Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and

You are here:  Home >>  News >>  Market News >>  Launch woes, crossed fingers, a 'bulletproof' FDA review and more

Launch woes, crossed fingers, a 'bulletproof' FDA review and more

January 10, 2019 By fiercepharma

The J.P. Morgan Healthcare Conference opened Tuesday with some anticipation for GlaxoSmithKline CEO Emma Walmsley's talk, what with the pharma giant's recent deal to buy cancer drugmaker Tesaro. And ahead of Amgen CEO Bob Bradway's morning presentation, the company rolled out another round of price cuts on its cholesterol drug Repatha, which Bradway talked up along with its new migraine drug Aimovig.


But pricing hasn't been much on the agenda, except at Alexion, which says it needs an entirely new strategy. What has? Drug launches—Lilly's Aimovig rival Emgality, for one—and hoped-for FDA nods; diabetes rivalries and deal integrations; FDA tea leaves and, yes, one unexpected tax bill.


We're chronicling the daily events with continuously updated roundups, from news stories to executive remarks to excerpts from our own sideline interviews. If you missed our Monday rundown, with its latest additions a few hours before Tuesday's schedule began, find it here. And for all our FiercePharma coverage over the course of the conference, keep tabs on this page, and look here for FierceBiotech's own news.

Add a comment
Click here to Login or to Register for free. You will be taken back to your selected item after Login/Registration.
More>> MarketNews
More>> Editors’Picks
More>> TopStories
More>> HotTags
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53
live chat